Telescope Innovations and Pfizer Sign Master Collaborative Research Agreement
Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) has signed a master collaborative research agreement with Pfizer Inc. to develop technology aimed at accelerating pharmaceutical R&D through automation, robotics, and artificial intelligence. The multi-year agreement focuses on deploying Self-Driving Laboratories (SDLs), which can optimize material properties and chemical synthesis methods up to 100x faster than traditional research methods.
The collaboration builds on Telescope's previous success in commercializing its DirectInject-LC™ automation product for online chemistry analysis. A joint steering committee will guide the technology development projects, ensuring Telescope's SDL technology is well-positioned for the pharmaceutical industry. This partnership could significantly reduce the time and cost of developing new pharmaceuticals, potentially providing a key competitive advantage in the industry.
Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ha firmato un accordo di collaborazione per la ricerca con Pfizer Inc. per sviluppare tecnologie volte ad accelerare la R&D farmaceutica attraverso automazione, robotica e intelligenza artificiale. L'accordo pluriennale si concentra sull'implementazione dei Laboratori Autonomi (SDL), che possono ottimizzare le proprietà dei materiali e i metodi di sintesi chimica fino a 100 volte più velocemente rispetto ai metodi di ricerca tradizionali.
La collaborazione si basa sul precedente successo di Telescope nella commercializzazione del suo prodotto di automazione DirectInject-LC™ per l'analisi chimica online. Un comitato di direzione congiunto guiderà i progetti di sviluppo tecnologico, assicurando che la tecnologia SDL di Telescope sia ben posizionata per l'industria farmaceutica. Questa partnership potrebbe ridurre significativamente i tempi e i costi dello sviluppo di nuovi farmaci, fornendo potenzialmente un vantaggio competitivo chiave nel settore.
Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ha firmado un acuerdo de colaboración para la investigación con Pfizer Inc. para desarrollar tecnología destinada a acelerar la I+D farmacéutica a través de automatización, robótica e inteligencia artificial. El acuerdo a largo plazo se centra en desplegar Laboratorios Autónomos (SDL), que pueden optimizar las propiedades de los materiales y los métodos de síntesis química hasta 100 veces más rápido que los métodos de investigación tradicionales.
La colaboración se basa en el éxito previo de Telescope en la comercialización de su producto de automatización DirectInject-LC™ para análisis químico en línea. Un comité de dirección conjunto guiará los proyectos de desarrollo tecnológico, asegurando que la tecnología SDL de Telescope esté bien posicionada para la industria farmacéutica. Esta asociación podría reducir significativamente el tiempo y el costo de desarrollar nuevos medicamentos, proporcionando potencialmente una ventaja competitiva clave en la industria.
탐스코프 이노베이션스 코프(Telescope Innovations Corp.)(CSE: TELI)(OTCQB: TELIF)는 화이자(Pfizer Inc.)와 마스터 협업 연구 계약을 체결하여 자동화, 로봇 기술 및 인공지능을 통해 제약 R&D를 가속화하는 기술을 개발합니다. 이 다년간 계약은 자율주행 실험실(SDLs)의 배치에 중점을 두며, 이는 전통적인 연구 방법보다 100배 더 빠르게 물질의 성질과 화학 합성 방법을 최적화할 수 있습니다.
이 협력은 탐스코프가 온라인 화학 분석을 위한 DirectInject-LC™ 자동화 제품을 상용화한 이전의 성공을 기반으로 합니다. 합동 운영 위원회가 기술 개발 프로젝트를 안내하여 탐스코프의 SDL 기술이 제약 산업에 잘 적합하도록 할 것입니다. 이 파트너십은 신약 개발의 시간과 비용을 크게 줄일 수 있으며, 제약 산업에서 주요 경쟁 우위를 제공할 가능성이 있습니다.
Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) a signé un accord de recherche collaboration maître avec Pfizer Inc. pour développer des technologies visant à accélérer la R&D pharmaceutique grâce à l'automatisation, la robotique et l'intelligence artificielle. L'accord pluriannuel se concentre sur le déploiement de Laboratoires Autonomes (SDL), capables d'optimiser les propriétés des matériaux et les méthodes de synthèse chimique jusqu'à 100 fois plus vite que les méthodes de recherche traditionnelles.
Cette collaboration s'appuie sur le succès précédent de Telescope dans la commercialisation de son produit d'automatisation DirectInject-LC™ pour l'analyse chimique en ligne. Un comité de pilotage conjoint orientera les projets de développement technologique, veillant à ce que la technologie SDL de Telescope soit bien positionnée pour l'industrie pharmaceutique. Ce partenariat pourrait réduire considérablement le temps et le coût de développement de nouveaux médicaments, offrant potentiellement un avantage concurrentiel clé dans l'industrie.
Die Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) hat einen Master-Kooperationsforschungsvertrag mit Pfizer Inc. unterzeichnet, um Technologien zu entwickeln, die darauf abzielen, die pharmazeutische F&E durch Automatisierung, Robotik und künstliche Intelligenz zu beschleunigen. Der mehrjährige Vertrag konzentriert sich auf die Implementierung von Selbstfahrenden Laboren (SDLs), die die Materialeigenschaften und chemischen Synthesemethoden bis zu 100-mal schneller optimieren können als traditionelle Forschungsmethoden.
Die Zusammenarbeit baut auf den bisherigen Erfolgen von Telescope bei der Kommerzialisierung seines Automatisierungsprodukts DirectInject-LC™ für die Online-Chemieanalyse auf. Ein gemeinsames Steuerungskomitee wird die technologischen Entwicklungsprojekte leiten, um sicherzustellen, dass die SDL-Technologie von Telescope gut für die pharmazeutische Industrie positioniert ist. Diese Partnerschaft könnte die Zeit und Kosten für die Entwicklung neuer Arzneimittel erheblich senken, wodurch potenziell ein wichtiger Wettbewerbsvorteil in der Branche entsteht.
- Multi-year collaborative agreement with Pfizer, a major pharmaceutical company
- Focus on developing Self-Driving Laboratories (SDLs) that can accelerate R&D up to 100x faster
- Potential to significantly reduce time and cost of new pharmaceutical development
- Previous success in commercializing DirectInject-LC™ automation product
- Joint steering committee to guide technology development projects
- None.
Funding from and collaboration with Pfizer could facilitate Telescope's growth and R&D advancement
Vancouver, British Columbia--(Newsfile Corp. - July 31, 2024) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ("Telescope" or the "Company"), a developer of enabling technologies and services for the global pharmaceutical and chemical industries, is pleased to announce the execution of a master collaborative research agreement (the "Agreement") with Pfizer Inc. ("Pfizer"). Under the multi-year Agreement, Pfizer and Telescope will collaboratively develop technology to help potentially accelerate pharmaceutical R&D through automation, robotics, and artificial intelligence.
Certain technology development efforts will focus on the deployment of Self-Driving Laboratories ("SDLs"), a leading-edge approach to chemistry research guided by artificial intelligence, advanced process analytical technology, and executed by robotic automation (Figure 1). SDLs are capable of optimizing material properties and chemical synthesis methods up to 100x faster than traditional research methods.[1] Thus, it is estimated that SDLs will significantly reduce the time and cost of developing new pharmaceuticals. Telescope's work in this area has already resulted in the successful commercialization of its automation product for online chemistry analysis, DirectInject-LC™, which was supported by prior engagements with Pfizer to establish proof-of-concept automation workflows.
Figure 1. Self-Driving Laboratories (SDLs) combine artificial intelligence with robotic automation to accelerate R&D. SDLs provide key competitive advantages in the pharmaceutical and fine chemical industries.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8923/218267_7c119c0044d48b1d_001full.jpg
Under the present Agreement, a joint steering committee with members from both companies will guide the technology development projects. This alignment is intended to ensure that Telescope's SDL technology is ideally positioned for deployment in the pharmaceutical industry.
"SDLs represent the next horizon in process chemistry automation and digitalization, potentially enabling researchers to develop and scale up new chemicals and materials faster than ever before," commented Henry Dubina, Telescope CEO. "We are grateful for Pfizer's support and collaboration as we pioneer this technology, and look forward to developing SDLs to meet market needs in the long term."
About Telescope
Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.
On behalf of the Board,
Telescope Innovations Corp.
Jeffrey Sherman, Chief Operating Officer
E: jeff@telescopeinn.com
Forward-Looking Information
Forward-looking information is based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information.
Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with the global COVID-19 pandemic; general economic conditions; adverse industry events; the Company's ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the ability of the Company to implement its business strategies; competition; and other assumptions, risks and uncertainties.
Forward-looking statements in this document include expectations surrounding funding from and collaboration with Pfizer to facilitate Telescope's growth and R&D advancement, Pfizer and Telescope's ability to collaboratively develop technology to accelerate pharmaceutical R&D, the deployment of Self-Driving Laboratories, estimates that SDLs will reduce the time and cost of developing new pharmaceuticals, the joint steering committee intended to guide the technology development projects, the development of SDLs to meet market needs in the long term, and all other statements that are not statements of historical fact.
The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
[1] (a) Ament, S. et al. Sci. Adv. 2021, 7(51) , eabg4930. (b) Macleod, P. et al.Nat. Commun. 2022, 13, 995.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218267
FAQ
What is the purpose of the agreement between Telescope Innovations and Pfizer?
How much faster can Self-Driving Laboratories (SDLs) optimize material properties and chemical synthesis methods?
What is Telescope Innovations' stock symbol on the OTCQB?
What product has Telescope Innovations already commercialized through prior engagements with Pfizer?
